ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,747.10
      1.48%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. AbbVie Inc (ABBV)

      7. AbbVie Inc (ABBV) News

      ABBV

      AbbVie (ABBV)

      AbbVie Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      11/29/20238:45AMPR Newswire (US)AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)NYSE:ABBVAbbVie Inc
      11/27/20237:00AMPR Newswire (US)AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular LymphomaNYSE:ABBVAbbVie Inc
      11/20/20238:45AMPR Newswire (US)Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day EverNYSE:ABBVAbbVie Inc
      11/16/20234:21PMAllPennyStocks.comTake Part in the Next Generation of Spinal Cord Injury Treatments with These CompaniesNYSE:ABBVAbbVie Inc
      11/16/20234:21PMAllPennyStocks.comTake Part in the Next Generation of Spinal Cord Injury Treatments with These CompaniesNYSE:ABBVAbbVie Inc
      11/16/20237:00AMPR Newswire (US)Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of MigraineNYSE:ABBVAbbVie Inc
      11/13/20234:05PMGlobeNewswire Inc.NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-YearNYSE:ABBVAbbVie Inc
      11/08/20238:45AMPR Newswire (US)Natrelle® Unveils New "For Every BODY" CampaignNYSE:ABBVAbbVie Inc
      11/06/20231:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ABBVAbbVie Inc
      11/02/20238:31AMPR Newswire (US)Roundhill Investments Launches Dividend Monarchs ETF (NYSE Arca: KNGS)NYSE:ABBVAbbVie Inc
      11/01/20232:27PMDow Jones NewsAldeyra Shares Continue to Rally After AbbVie Agrees to Licensing OptionNYSE:ABBVAbbVie Inc
      11/01/20238:48AMDow Jones NewsAldeyra Shares Rally After AbbVie Licensing Deal on Eye DrugNYSE:ABBVAbbVie Inc
      11/01/20238:45AMPR Newswire (US)BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never BeforeNYSE:ABBVAbbVie Inc
      10/30/20238:00AMGlobeNewswire Inc.NEXGEL Secures Supply Agreement with AbbVieNYSE:ABBVAbbVie Inc
      10/27/20238:16AMDow Jones NewsAbbVie Raises Quarterly Dividend by 4.7% to $1.55NYSE:ABBVAbbVie Inc
      10/27/20237:49AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      10/27/20237:38AMPR Newswire (US)AbbVie Reports Third-Quarter 2023 Financial ResultsNYSE:ABBVAbbVie Inc
      10/27/20237:10AMIH Market NewsFriday’s Wall Street Highlights: Enphase Energy, GM, Intel, Sanofi, Masimo, and moreNYSE:ABBVAbbVie Inc
      10/24/20238:30AMPR Newswire (US)Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar LinesNYSE:ABBVAbbVie Inc
      10/19/20235:06PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      10/19/20235:04PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      10/19/20238:45AMPR Newswire (US)Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom ProjectNYSE:ABBVAbbVie Inc
      10/17/20237:05AMPR Newswire (Canada)AbbVie's RINVOQ® (upadacitinib) Receives Health Canada Approval as the First and Only Oral Therapy for the Treatment of Adults with Moderately to Severely Active Crohn's DiseaseNYSE:ABBVAbbVie Inc
      10/17/20237:05AMPR Newswire (Canada)AbbVie reçoit l'approbation de Santé Canada pour l'emploi de RINVOQ® (upadacitinib) en tant que premier et seul traitement à administration orale destiné aux adultes atteints de la maladie de Crohn modérément à fortement évolutiveNYSE:ABBVAbbVie Inc
      10/17/20237:00AMPR Newswire (Canada)AbbVie obtient une autorisation de mise en marché avec conditions de Santé Canada pour EPKINLY (MC) (epcoritamab injectable/epcoritamab pour injection), le premier et le seul anticorps bispécifique administré par voie sous-cutanée et destiné au traitNYSE:ABBVAbbVie Inc
      10/17/20237:00AMPR Newswire (Canada)AbbVie's EPKINLY™ (epcoritamab injection/epcoritamab for injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell LymphNYSE:ABBVAbbVie Inc
      10/15/202311:15AMPR Newswire (US)AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary EndpointsNYSE:ABBVAbbVie Inc
      10/12/20235:17PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      10/12/20236:29AMDow Jones NewsAbbVie Advancing Rinvoq to Phase 3 Studies in VitiligoNYSE:ABBVAbbVie Inc
      10/12/20235:25AMPR Newswire (US)AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3NYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV